Zurich Insurance Group Ltd FI raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 0.0% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,088,656 shares of the biopharmaceutical company’s stock after buying an additional 298 shares during the quarter. Pfizer comprises 0.9% of Zurich Insurance Group Ltd FI’s portfolio, making the stock its 19th largest holding. Zurich Insurance Group Ltd FI’s holdings in Pfizer were worth $47,161,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently bought and sold shares of the company. Weybosset Research & Management LLC lifted its holdings in Pfizer by 2.0% in the second quarter. Weybosset Research & Management LLC now owns 12,847 shares of the biopharmaceutical company’s stock valued at $557,000 after acquiring an additional 250 shares during the period. Cottage Street Advisors LLC boosted its holdings in shares of Pfizer by 4.0% in the 4th quarter. Cottage Street Advisors LLC now owns 6,677 shares of the biopharmaceutical company’s stock worth $291,000 after purchasing an additional 255 shares during the period. Financial Gravity Wealth Inc. boosted its holdings in shares of Pfizer by 33.2% in the 2nd quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 257 shares during the period. Intl Fcstone Inc. boosted its holdings in shares of Pfizer by 2.4% in the 2nd quarter. Intl Fcstone Inc. now owns 11,140 shares of the biopharmaceutical company’s stock worth $483,000 after purchasing an additional 261 shares during the period. Finally, Lee Financial Co boosted its holdings in shares of Pfizer by 6.2% in the 2nd quarter. Lee Financial Co now owns 4,569 shares of the biopharmaceutical company’s stock worth $198,000 after purchasing an additional 265 shares during the period. 71.68% of the stock is owned by institutional investors and hedge funds.
In other news, major shareholder Pfizer Inc bought 50,000 shares of Pfizer stock in a transaction on Tuesday, September 17th. The stock was acquired at an average price of $18.00 per share, with a total value of $900,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Scott Gottlieb bought 3,000 shares of Pfizer stock in a transaction on Friday, August 23rd. The shares were purchased at an average cost of $34.72 per share, with a total value of $104,160.00. Following the acquisition, the director now directly owns 3,000 shares of the company’s stock, valued at $104,160. The disclosure for this purchase can be found here. 0.09% of the stock is owned by corporate insiders.
PFE stock traded up $0.27 on Friday, hitting $36.79. 21,294,470 shares of the company’s stock were exchanged, compared to its average volume of 19,822,398. Pfizer Inc. has a 12-month low of $33.97 and a 12-month high of $46.47. The firm has a 50 day moving average price of $36.04 and a two-hundred day moving average price of $40.59. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47. The stock has a market cap of $201.88 billion, a P/E ratio of 12.26, a price-to-earnings-growth ratio of 2.90 and a beta of 0.65.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.05. The business had revenue of $13.26 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The company’s quarterly revenue was down 1.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.77 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.81 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, August 2nd were issued a dividend of $0.36 per share. The ex-dividend date was Thursday, August 1st. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.91%. Pfizer’s payout ratio is currently 48.00%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Article: How to execute a trade ex-dividend strategy?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.